Yangkang Asset Teams up with FaLong Pharmaceuticals to Launch an International Promotion Strategy for Traditional Chinese Medicine, Creating a New Global Health Channel
On July 4, 2025, Yangkang Asset Management Co., Ltd. (the Taiwan headquarters of Dingying Group) officially signed a strategic cooperation agreement with FaLong Pharmaceuticals in the United States. Both parties will jointly launch an international promotion plan for the Traditional Chinese Medicine industry, creating a fully integrated platform covering research and development, manufacturing, clinical applications, and market operations.
This strategic cooperation combines Yangkang Asset’s capital strategy planning and industry matchmaking capabilities in the Asia-Pacific region with FaLong Pharmaceuticals’ clinical application, pharmaceutical distribution, and regulatory experience in the U.S. market. Together, they will promote the modernization and globalization of the Traditional Chinese Medicine industry through product design, cross-border promotion, channel implementation, and smart health technology applications.
As the primary platform for Dingying Group’s cross-border capital services, Yangkang Asset continues to integrate resources in innovation, biotechnology, medical care, and health sectors, promoting the fusion of technology and traditional industries. This collaboration with FaLong Pharmaceuticals lays a crucial foundation for Yangkang’s strategic direction in medical health and global promotion.
FaLong Pharmaceuticals has long been established in the U.S. market, with multiple clinical achievements and sales channels for botanical drugs, possessing capabilities in cross-border product design, regulatory consultation, and platform promotion. The cooperation agreement stipulates that both parties will promote the establishment of demonstration channels and integration of data platforms, expanding to smart medical and functional health applications.
The Board of Directors of Yangkang Asset stated: “Traditional Chinese Medicine is not only a cultural heritage of the East but also a new opportunity for the global health industry. Our cooperation with FaLong Pharmaceuticals will build the most complete resource bridge for Traditional Chinese Medicine to go global.”
The cooperation plan officially starts from today, with the first phase expected to establish demonstration sites in Taiwan and promote sales layouts in the Asia-Pacific region and product exports to the U.S. market.
Choosing Dingying means standing on the shoulders of giants. Dingying Group will collaborate with more innovative partners to create global health solutions that integrate technology and culture.